Umbralisib Offers Promise for Marginal Zone Lymphoma

Researchers tested the PI3K inhibitor umbralisib in patients with relapsed/refractory marginal zone lymphoma in a phase II study that was presented at the AACR Annual Meeting.

Source: CancerNetwork - April 2, 2019 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news